Antifungal prophylaxis and treatment in patients with hematological malignancies

References

• Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis.48(12),1695–1703 (2009).
   PubMed Web of Science ®Google Scholar
• Sipsas NV, Lewis RE, Tarrand J et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer115(20),4745–4752 (2009).
   PubMed Web of Science ®Google Scholar
• Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br. J. Haematol.110(2),273–284 (2000).
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood100(13), 4358–4366 (2000).
   Web of Science ®Google Scholar
• Von Eiff M, Roos N, Schulten R, Hesse M, Zuhlsdorf M, van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration62, 341–347 (1995).
   PubMed Web of Science ®Google Scholar
• Rossini F, Verga M, Pioltelli P et al. Incidence and outcome of pneumonia in patients with acute leukemia receiving first induction therapy with anthracycline-containing regimens. Hematologica85(12), 1255–1260 (2000).
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin. Infect. Dis.34(1), 7–14 (2002).
   PubMed Web of Science ®Google Scholar
• Pfeiffer CD, Safdar N, Fine JP. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin. Infect. Dis.42(10), 1417–1427 (2006).
   PubMed Web of Science ®Google Scholar
• Maertens JA, Klont R, Masson C et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin. Infect. Dis.44(10), 1329–1336 (2007).
   PubMed Web of Science ®Google Scholar
• Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin. Infect. Dis.40(12), 1762–1769 (2005).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Shoham S, Petraitiene R et al. Detections of galactomannan antigenemia in patients receiving piperacillin–tazobactam and correlations between in vitro, in vivo and clinical properties of the drug–antigen interactions. J. Clin. Microbiol.42(10), 4744–4748 (2004).
   PubMed Web of Science ®Google Scholar
• Mattei D, Rapezzi D, Mordini N et al. False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin–clavulanic acid treatment. J. Clin. Microbiol.42(11), 5362–5363 (2004).
   PubMed Web of Science ®Google Scholar
• Tamma P. The galactomannan antigen assay. Pediatr. Infect. Dis. J.26(7), 641–642 (2007).
   PubMed Web of Science ®Google Scholar
• Asano-Mori Y, Kanda Y, Oshima K et al. False positive Aspergillus galactomannan antigenemia after hematopoietic stem cell transplantation. J. Antimicrob. Chemother.61(2), 411–416 (2008).
   PubMed Web of Science ®Google Scholar
• Klont RR, Mennink-Kersten MASH, Verweij PE. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin. Infect. Dis.39, 1467–1474 (2004).
   PubMed Web of Science ®Google Scholar
• Becker MJ, Lugtenburg EJ, Cornelissen JJ, van der Schee C, Hoogsteden HC, de Marie S. Galactomannan detection in computerized tomography-based bronchoalveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br. J. Haematol.121, 448–457 (2003).
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the 1,3-β-D-glucan assay as an aid to diagnosis of fungal infection in humans. Clin. Infect. Dis.41(5), 654–659 (2005).
   PubMed Web of Science ®Google Scholar
• White PL, Linton CJ, Perry MD, Johnson EM, Barnes RA. The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting. Clin. Infect. Dis.42(4), 487–489 (2006).
   PubMed Web of Science ®Google Scholar
• Perfect JR, Klotman ME, Gilbert CC et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J. Infect. Dis.165(5), 891–897 (1992).
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Estey E, Raad I et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction: chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer97(2), 450–456 (2003).
   PubMed Web of Science ®Google Scholar
• Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transpant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood96(6), 2055–2061 (2000).
   PubMed Web of Science ®Google Scholar
• Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood103(4), 1527–1533 (2004).
   PubMed Web of Science ®Google Scholar
• Van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis.39(10), 1407–1416 (2004).
   PubMed Web of Science ®Google Scholar
• Robenshtok E, Gafter-Gvili A, Goldberg E et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J. Clin. Oncol.25(34), 5471–5489 (2007).
   PubMed Web of Science ®Google Scholar
• Marr KA. Invasive Candida infections: the changing epidemiology. Oncology (Huntingt.)18, 9–14 (2004).
   PubMedGoogle Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis.34, 909–917 (2002).
   PubMed Web of Science ®Google Scholar
• Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicentre, randomized trial. Ann. Intern. Med.138(9), 705–713 (2003).
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Prentice A, Gorschluter M et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3597 patients. J. Clin. Oncol.21(24), 4615–4626 (2003).
   PubMed Web of Science ®Google Scholar
• Siwek GT, Pfaller MA, Polgreen PM et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn. Microbiol. Infect. Dis.55(3), 209–212 (2006).
   PubMed Web of Science ®Google Scholar
• Wingard JR, Carter SL, Walsh TJ. Results of a randomized, double-blind trial of fluconazole versus voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients. Blood (ASH Annual Meeting Abstracts)110(11), 163 (2007).
   Web of Science ®Google Scholar
• Siwek GT, Dodgson KJ, Magalheas-Silverman M et al. Invasive zygomycosis in hematopoietic stem-cell transplant recipients receiving voriconazole prophylaxis. Clin. Infect. Dis.39, 584–587 (2004).
   PubMed Web of Science ®Google Scholar
• Trifilio S, Bennett CL, Yarnold PR et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant39(7), 425–429 (2007).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ et al. Posaconazole versus fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Eng. J. Med.356(4), 348–359 (2007).
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host-disease. N. Engl. J. Med.356(4), 335–347 (2007).
   PubMed Web of Science ®Google Scholar
• Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O’Brien S. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob. Agents Chemother.50(1), 143–147 (2006).
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Schmidt GM, Tegtmeier BR et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J. Clin. Oncol.12(4), 827–834 (1994).
   PubMed Web of Science ®Google Scholar
• Penack O, Schwartz S, Martus P et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann. Oncol.17, 1306–1312 (2006).
   PubMed Web of Science ®Google Scholar
• Rijnders BJ, Cornelissen JJ, Slobbe L et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin. Infect. Dis.46, 1401–1408 (2008).
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Pautas C, Maury S et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin. Infect. Dis.48, 1042–1051 (2009).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med.340(10), 764–771 (1999).
   PubMed Web of Science ®Google Scholar
• Boogaerts M, Winston DJ, Bow EJ et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann. Intern. Med.135(6), 412–422 (2001).
   PubMed Web of Science ®Google Scholar
• Schuler U, Bammer S, Aulitzky WE et al. Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy. Onkologie30(4), 185–191 (2007).
   PubMedGoogle Scholar
• Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med.346(4), 225–234 (2002).
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Cornely OA, Buchardt A et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother.50(2), 658–666 (2006).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med.351(14), 1391–1402 (2004).
   PubMed Web of Science ®Google Scholar
• Tamura K, Urabe A, Yoshida M et al. Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infection in patients with haematological diseases. Leuk. Lymphoma50(1), 92–100 (2009).
   PubMed Web of Science ®Google Scholar
• Segal BH, Almyroudis NG, Battiwalla M et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin. Infect. Dis.44(3), 402–409 (2007).
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomography based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin. Infect. Dis.41, 1242–1250 (2005).
   PubMed Web of Science ®Google Scholar